Author/Authors :
Stéphane Angenault، نويسنده , , Sylvie Thirot، نويسنده , , Frédéric Schmidt، نويسنده , , Claude Monneret، نويسنده , , Bruno Pfeiffer، نويسنده , , Pierre Renard، نويسنده ,
Abstract :
A glucuronide-based prodrug of SN-38 (7-ethyl-10-hydroxycamptothecin) has been synthesized for use in a Prodrug MonoTherapy Strategy (PMT). Since this prodrug is significantly less cytotoxic than SN-38 itself and efficiently releases the drug in vitro in the presence of β- -glucuronidase, it can be considered as an appropriate candidate for cancer treatment by a PMT strategy.
